CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Summary

Chimeric antigen receptor (CAR-T) engineered T cells against the CD19 protein have been shown to be effective against acute lymphoma and lymphocytic leukemia and are approved by the US (FDA), European (EMA) and Health Basel. However, little information exists on using CD19CAR for treatment of recurrent or irresponsible to previous treatment acute myeloid leukemia. The proposed study will include patients with recurrent disease or those with disease irresponsible to common treatments and they will be treated with CAR-T CD19.

Timeline

Start

2020-02-18

Primary completion

2024-12-01

Completion

2024-12-01

Drugs

Indications